CSO and Co-founder

Damian co-founded Kynos after discovering KMO inhibition as new target at the interface of inflammation, immunity and metabolism, building on a 15-year translational KMO inhibitor programme, including a prestigious GSK-University of Edinburgh DPAc Collaboration. He led the spin-out and licensing from the University of Edinburgh, driven by his passion and determination to deliver innovative solutions to challenging and unmet medical needs. Damian is jointly trained in the UK and USA in translational science and business leadership, and as a surgeon in liver and pancreas disease. Damian holds the 1777 Chair of Surgery at the University of Edinburgh and an MRC Senior Clinical Fellowship.​​

LinkedIn